SCHEMBL18019201

SCHEMBL18019201

CC(C)C[C@H](NC(=O)OC(C)(C)C)C(=O)NS(=O)(=O)c1ccc(O)c2ccccc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSL P07711 2/20 0.46
CTSB P07858 1/20 0.46
CTSS P25774 1/20 0.46
CTSK P43235 1/20 0.46
REN P00797 3/20 0.45
MAP1LC3B Q9GZQ8 1/20 0.45
MAP1LC3A Q9H492 1/20 0.45
AAK1 Q2M2I8 1/20 0.45
BCL2 P10415 1/20 0.44
USP30 Q70CQ3 1/20 0.43
CCKBR P32239 3/20 0.42
MMP13 P45452 2/20 0.42
KDM4E B2RXH2 1/20 0.42
ALDH1A1 P00352 1/20 0.42
PLA2G1B P04054 1/20 0.42
MAPT P10636 1/20 0.42
HPGD P15428 1/20 0.42
XBP1 P17861 1/20 0.42
HTT P42858 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19801165 0.88 FABP4 (0.44) CTSLCTSBCTSSCTSKREN
SCHEMBL18019199 0.86 CTSS (0.49) CTSLCTSBCTSSCTSKREN
SCHEMBL18019164 0.83 PTGS2 (0.44) CTSLCTSBCTSSCTSKREN
SCHEMBL18019117 0.82 BCL2 (0.61) CTSLCTSBCTSSCTSKREN
SCHEMBL19792926 0.82 CTSK (0.48) CTSLCTSBCTSSCTSKREN
SCHEMBL19792924 0.82 CTSS (0.48) CTSLCTSBCTSSCTSKREN
SCHEMBL18019118 0.81 CTSK (0.50) CTSLCTSBCTSSCTSKREN
SCHEMBL18019202 0.80 BCL2 (0.63) CTSLCTSBCTSSCTSKREN
SCHEMBL19792930 0.78 BCL2 (0.47) CTSLCTSBCTSSCTSKREN
SCHEMBL19801193 0.78 LARS1 (0.62) CTSLCTSBCTSSCTSKREN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11072581-B2 N-acyl-arylsulfonamide derivatives as aminoacyl-tRNA synthetase inhibitors Oxford Drug Design Limited (GB) 2021-07-27 US disclosed
US-20180022696-A1 NOVEL N-ACYL-ARYLSULFONAMIDE DERIVATIVES AS AMINOACYL-TRNA SYNTHETASE INHIBITORS THE LATVIAN INSTITUTE OF ORGANIC SYNTHESIS (LV) 2018-01-25 US disclosed
WO-2016129983-A1 NOVEL N-ACYL-ARYLSULFONAMIDE DERIVATIVES AS AMINOACYL-TRNA SYNTHETASE INHIBITORS LATVIAN INSTITUTE OF ORGANIC SYNTHESIS (LV) 2016-08-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180022696-A1 NOVEL N-ACYL-ARYLSULFONAMIDE DERIVATIVES AS AMINOACYL-TRNA SYNTHETASE INHIBITORS AARS1, GARS1, ASNS CTSL 1183/4885CTSB 1645/4885CTSS 436/4885
US-11072581-B2 N-acyl-arylsulfonamide derivatives as aminoacyl-tRNA synthetase inhibitors AARS1, ASNS, GARS1 CTSL 1122/4885CTSB 1682/4885CTSS 424/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.